A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies

Protocol: 
AAAR7748
Phase: 
I/II

A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies

The purpose of this study is to determine the highest dose of the study drug
that can be given safely to people with certain cancers. The study will also
look at how effective the study drug is in treating certain cancers. The
study drug is PLX2853. The participants in this study will be the first
people to receive PLX2853.

Are you Eligible? (Inclusion Criteria)

1. Do you have a confirmed solid tumor?

2. Have you had treatment for your disease before? Or does a standard
therapy not exist for your disease?

3. Are you 18 years of age or older?

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States